

Strain	Genotype and RNAi treatment	Trial	Mean lifespan \pm SEM (days)	% Differences	N (total)	<i>p</i>
GA303	<i>rrf-3</i> ; <i>daf-2</i> control RNAi	1	29.2 \pm 0.98		73 (98)	-
GA303	<i>rrf-3</i> ; <i>daf-2 aakg-1</i> RNAi	1	26.0 \pm 0.71	-31	74 (84)	<0.0001 ^a
GA303	<i>rrf-3</i> ; <i>daf-2 aakg-2</i> RNAi	1	30.4 \pm 1.21	+4.2	35 (43)	NS ^a
GA303	<i>rrf-3</i> ; <i>daf-2 aakg-3</i> RNAi	1	28.2 \pm 1.11	-3.4	35 (43)	NS ^a
NL2099	<i>rrf-3</i> control RNAi	2	14.8 \pm 0.52		86 (99)	-
GA303	<i>rrf-3</i> ; <i>daf-2</i> control RNAi	2	28.4 \pm 1.08		86 (88)	<0.0001 ^b
GA303	<i>rrf-3</i> ; <i>daf-2 aakg-1</i> RNAi	2	28.7 \pm 0.79	+0.8	103 (116)	NS ^a
GA303	<i>rrf-3</i> ; <i>daf-2 aakg-2</i> RNAi	2	29.2 \pm 1.07	+2.6	75 (83)	NS ^a
GA303	<i>rrf-3</i> ; <i>daf-2 aakg-3</i> RNAi	2	32.3 \pm 0.65	+13.8	104 (104)	NS ^a
NL2099	<i>rrf-3</i> control RNAi	3	13.7 \pm 0.47		82 (82)	-
GA303	<i>rrf-3</i> ; <i>daf-2</i> control RNAi	3	26.5 \pm 0.83		106 (118)	<0.0001 ^b
GA303	<i>rrf-3</i> ; <i>daf-2 aakg-1</i> RNAi	3	24.9 \pm 0.79	-6.2	129 (129)	NS ^a
GA303	<i>rrf-3</i> ; <i>daf-2 aakg-2</i> RNAi	3	26.0 \pm 0.90	-1.9	98 (98)	NS ^a
GA303	<i>rrf-3</i> ; <i>daf-2 aakg-3</i> RNAi	3	31.3 \pm 0.61	+18.1	125 (125)	<0.0001 ^a
NL2099	<i>rrf-3</i> control RNAi	4	12.6 \pm 0.34		119 (123)	-
GA303	<i>rrf-3</i> ; <i>daf-2</i> control RNAi	4	26.6 \pm 0.86		127 (127)	<0.0001 ^b
GA303	<i>rrf-3</i> ; <i>daf-2 aakg-1</i> RNAi	4	23.4 \pm 1.09	-11.9	70 (71)	0.005 ^a
GA303	<i>rrf-3</i> ; <i>daf-2 aakg-2</i> RNAi	4	25.9 \pm 0.92	-2.5	109 (109)	NS
GA303	<i>rrf-3</i> ; <i>daf-2 aakg-3</i> RNAi	4	24.8 \pm 0.91	-6.8	85 (86)	NS

Table S9. RNAi targeted to *aakg-1*, *aakg-2* or *aakg-3* does not consistently suppress *daf-2* mutant longevity.